Physician profile
Thomas J Thysseril
NPI 1699751909
$2,079.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,820 · 2020: $260.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $378.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $287.48 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $230.07 | 2019 | |
| Lundbeck LLC | $188.76 | 2019-2020 | |
| Allergan, INC. | $159.99 | 2019-2020 | |
| Bausch Health US, LLC | $156.96 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $150.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.00 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $114.54 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $82.89 | 2019 | |
| Alkermes, INC. | $75.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.52 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $36.91 | 2019 | |
| Shire North American Group INC | $30.49 | 2019 | |
| Merck Sharp & Dohme LLC | $14.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Thysseril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.